Abstract:OBJECTIVE:To compare the differences in the clinicopathological and molecular biological features between the breast cancer patients with estrogen receptor (ER)+/progesterone receptor (PR)+ or ER+/PR- tumors.METHODS:The clinicopathological data of 3124 female breast cancer patients with known ER/PR expression status, 2220 being ER+/PR+ and 904 being ER+/PR-, and 1484 being ER-/PR-, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of c-erb and cathepsin D in the tumor specimens.RESULTS:The average peak onset age was 50 years in both the ER+/PR+ and ER+PR- patients, and the mean age of the ER+/PR+ patients was 52.40 years, not significantly different from that of the ER-/PR- patients (52.57 years, P = 0.709). The peak onset age of the ER+ patients was 50 years, significantly higher that that of the ER- patients (48 years, P = 0.001), and the mean age of the ER+ patients was 52.46 years, significantly higher than that of the ER- patients (51.42 years, P = 0.001). Univariate analysis showed that ER+/PR- tumors tended to be larger. 24.8% of the ER+/PR- patients had 4 or more metastatic lymph nodes, a rate significantly higher than that of the ER+/PR- patients (20.7%, P = 0.004). The tumors of 18% of the ER+/PR- patients were at the grade III, a rate significantly higher than that of the ER+/PR+ patients (13.5%, P = 0.008). The strong positivity rate of the ER+/PR+ tumors was 23.4%, ignorantly higher than hat of the ER+/PR- tumors (11.2%, P = 0.000). The c-erB-2 positive rate of the ER+/PR+ tumors was 19.7%, significantly lower than that of the ER+/PR- tumor group (28.7%, P = 0.000). The cathepsin D positive rate of the ER+/PR- group was 76.9%, significantly higher than that of the ER+/PR- group (71.9%, P = 0.005). Multivariate analysis indicated that positive PR expression was associated with the level of ER (OR = 1.792, 95% CI = 1.484 - 2.164, P = 0.000), cathepsin D (OR = 1.380, 95% CI = 1.023 - 1.862, P = 0.035) and c-erbB-2 (OR = 0.639, 95% CI = 0.463 - 0.883, P = 0.007).CONCLUSION:ER+/PR+ and ER+/PR- tumors may have identical etiology. The mechanism of whether PR is expressed in ER+ breast cancer may be caused by different factors, which causing many different aspects. According to these differences, new target of therapy may provide the possibility of improving the response and prognosis for patients with ER+/PR- tumors.

The Relationship Between Expressive Contents of the Estrogen Receptor and Progesterone Receptor and Each Kind of the Breast Hypertrophy

Estrogen receptor level and content change of IL-13 & TNF-α in different physiological stages in mice

THE RELATIONSHIP OF THE PROLIFERATION AND PHENOTYPIC MODULATION OF THE STROMAL CELLS AND THE EXPRESSION OF ESTROGEN RECEPTOR α IN BENIGN PROSTATIC HYPERPLASIA

Differential Regulating Effect on Estrogen Receptor Αand Β Expression in Female Rat Hippocampus and Cortex Regions Between Different Types of Estrogen Regents

The Predominant Proteins That React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight Between the Mammary Gland and Uterus in the Mouse and Rat.

Expression of HOXA 11 in Human Endometrial Hyperplasia and Adenocarcinoma

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

Concentrations of estrogen and progesterone in breast milk and their relationship with the mother's diet.

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

Relationship Between the Expression of PTEN, ER and PR and the Prognosis of TCRE in Endometrial Hyperplasia

Association Between Hormone Receptors And Her-2/Neu Is Age-Related

Expression of estrogen receptor α and β in endometrial disease during menopausal transition period

[Clinico-Pathological Features of ER+/PR+ and ER+/PR- Breast Tumors: a Comparative Study of 5211 Cases].

[Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].

Progesterone receptor and its correlation with DNA-binding function of estrogen receptor in human breast cancer

The expression of ER-α and ER-β in eutopic and ectopic endomerium epithelial cell of endometriosis.

[Expression and Significance of Estrogen Receptor Isoforms in the Development of Human Breast Carcinoma].

Retrospective study of the differences of biomarker expression between primary lesions of breast cancer and corresponding lymph node metastases

Progesterone Receptor and Progesterone Receptor B Isoform Expression and Their Clinical Significance in Endometrial Adenocarcinoma

The Immunohistochemical Profile of Mammary Tissue in Women With Macromastia and Its Potential Clinical Implications

Regulation of Human Progesterone Receptor Isoforms A and B in Uterine Endometrial Cardmoma by Estrogen